Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
495
Recruiting Now
495
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT07064473 Phase 3
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empag...
Condition
Diabetes Mellitus, Type 2
Enrollment
11,800 pts
Location
United States, Argentina, Australia
Sponsor
Boehringer Ingelheim
NCT06559241 Phase 3
Recruiting
Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical T...
Condition
Acute Ischemic Stroke
Enrollment
2,105 pts
Location
China
Sponsor
Capital Medical University
NCT05849779 Phase 3
Recruiting
Inhaled Sevoflurane for ARDS Prevention
Condition
Acute Respiratory Distress Syndrome
Enrollment
80 pts
Location
France
Sponsor
University Hospital, Clermont-
NCT06555003 Phase 3
Recruiting
DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metas...
Condition
Liver Neoplasm
Enrollment
116 pts
Location
Iran
Sponsor
Tehran University of Medical S
NCT06698796 Phase 3
Recruiting
A Study to Understand How the Study Medicine Dazukibart Works in People With Idi...
Condition
Dermatomyositis
Enrollment
211 pts
Location
United States, Argentina, Bulgaria
Sponsor
Pfizer
NCT05923073 Phase 3
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Acti...
Condition
Crohn's Disease
Enrollment
120 pts
Location
United States, Australia, Austria
Sponsor
Janssen Research & Development
NCT06841354 Phase 3
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Comb...
Condition
Triple Negative Breast Neoplasms
Enrollment
1,000 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT07621718 Phase 3
Recruiting
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Inve...
Condition
Pancreatic Cancer
Enrollment
670 pts
Location
United States
Sponsor
Revolution Medicines, Inc.
NCT06976190 Phase 3
Recruiting
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Tr...
Condition
Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment
446 pts
Location
China
Sponsor
Shanghai Miracogen Inc.
NCT05163288 Phase 3
Recruiting
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
Condition
Niemann-Pick Disease, Type C
Enrollment
53 pts
Location
United States, Australia, Czechia
Sponsor
IntraBio Inc
NCT06043973 Phase 3
Recruiting
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-sm...
Condition
Advanced Non-small Cell Lung Cancer
Enrollment
98 pts
Location
China
Sponsor
Qianfoshan Hospital
NCT07438496 Phase 3
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythema...
Condition
Lupus Erythematosus, Systemic
Enrollment
600 pts
Location
United States, Argentina, Australia
Sponsor
Janssen Research & Development
NCT07511127 Phase 3
Recruiting
Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in...
Condition
Hematologic Malignancy
Enrollment
218 pts
Location
China
Sponsor
Ruijin Hospital
NCT06857773 Phase 3
Recruiting
Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Comb...
Condition
Colorectal Neoplasms
Enrollment
306 pts
Location
Netherlands
Sponsor
The Netherlands Cancer Institu
NCT07190196 Phase 3
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adul...
Condition
Immunoglobulin G4 Related Disease
Enrollment
124 pts
Location
United States, Argentina, Belgium
Sponsor
Sanofi
NCT05553886 Phase 3
Recruiting
S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction
Condition
Chronic Heart Failure With Reduced Ejection Fraction
Enrollment
5 pts
Location
China
Sponsor
Shenzhen People's Hospital
NCT06669013 Phase 3
Recruiting
Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue ...
Condition
Bone Sarcoma
Enrollment
40 pts
Location
Russia
Sponsor
N.N. Petrov National Medical R
NCT06932562 Phase 3
Recruiting
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard ...
Condition
Multiple Myeloma
Enrollment
1,000 pts
Location
Australia, Austria, Croatia
Sponsor
European Myeloma Network B.V.
NCT07359846 Phase 3
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With...
Condition
Severe Asthma
Enrollment
786 pts
Location
United States, Japan
Sponsor
Generate Biomedicines
NCT03983369 Phase 3
Recruiting
Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in C...
Condition
Mucositis Oral
Enrollment
315 pts
Location
France
Sponsor
Gustave Roussy, Cancer Campus,
NCT06670196 Phase 3
Recruiting
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients...
Condition
Non-Small Cell Lung Cancer
Enrollment
420 pts
Location
China
Sponsor
Sichuan Kelun-Biotech Biopharm
NCT07090759 Phase 3
Recruiting
To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in...
Condition
Chronic Hepatitis b
Enrollment
526 pts
Location
China
Sponsor
Fujian Akeylink Biotechnology
NCT07478003 Phase 3
Recruiting
Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myoc...
Condition
STEMI - ST Elevation Myocardial Infarction
Enrollment
5,204 pts
Location
Denmark
Sponsor
Thomas Engstrom
NCT06694805 Phase 3
Recruiting
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + R...
Condition
HIV Infections
Enrollment
332 pts
Location
United States, Argentina, Belgium
Sponsor
ViiV Healthcare
NCT07132684 Phase 3
Recruiting
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukem...
Condition
AML, Adult
Enrollment
240 pts
Location
China
Sponsor
Institute of Hematology & Bloo
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology